Bundgaard H. Designs of Prodrugs. (1985). Elsevier. pp. 1-3.* |
Lee et al., 1996, J. Med. Chem. 39:2508-251. |
Robertson et al., 1996, Xenobiotica 26:559-569. |
Gniazdowsk et al., 1995, Gen. Pharmacol. 26:473-480. |
Monge, A. et al., 1994, J. Heterocyclic Chem. 31:1455-1460. |
Cholody, et al., 1991, J. Heterocyclic Chem. 28: 209-214. |
Denny et al. 1990, J. Med. Chem. 33:1288-1295. |
Mazerska et al., 1990, Anti-Cancer Drug Des. 5:169-187. |
Wilson et al., 1989, J. Med Chem. 32:23-30. |
Ferguson et al. 1987, Mutagenesis 2: 253-256. |
Mazerska et al., 1984, Eur. J. Med. Chem. 19:199-204. |
Pawlak et al., 1984, Cancer Res. 44:4829-4296. |
Cholody et al., 1983, Pol. J. Chem. 57:285-290. |
Hrabowska et al., 1982 Arzneimittel-Forschung 32:1013-6. |
Gniazdowski et al., 1982, Cancer Letters 15:73-79. |
Joseph et al., 1996, Proc. Natl. Acad. Sci. U.S.A. 93:8552-8557. |
Wysocka-Skrzela et al., 1981, Pol. J. Chem. 55:2211-2214. |
Sofina et al., 1980, Experimental Evaluation of Antitumor Drugs in the USA and USSR and Clinical Correlations. NIH Publication No. 80-1933. |
Wysocka-Skrzela et al., 1980, Pol. J. Chem. 54:619-623. |
Ledochowski, 1976, Mat. Med. Pol. 8:1-15. |
Kolodziejczyk et al., 1975, J. Labelled Compounds 11:385-394. |
Cain et al., 1974, J. Med. Chem. 173:922-930. |
Horowska et al., 1968, Roczniki Chemii, Ann. Soc. Chim. Polonorum 42:1351-5. |
Steck, E.A. et al., 1957, J. Am. Chem. Soc. 79:4414-4417. |
Yekundi, et al., 1957, Chem. Ber. 90:2448-2450. |